SCHEMBL6084065

SCHEMBL6084065

O=C(Nc1ccc(F)c(COc2cnccn2)c1)Nc1ncc(-c2ccc(Cl)cc2)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 0.53
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ABL1 P00519 1/20 0.41
AURKA O14965 1/20 0.40
KDR P35968 1/20 0.40
FLT3 P36888 1/20 0.40
NTRK1 P04629 1/20 0.40
HTT P42858 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
BLM P54132 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080735 0.80 BLM (0.55) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL6079674 0.80 RAB9A (0.49) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL6078723 0.78 BLM (0.43) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL6079773 0.77 MAPT (0.44) MEN1KMT2ARAB9AMAPTHTT
SCHEMBL6079515 0.77 BLM (0.42) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL6079119 0.77 ALDH1A1 (0.52) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL6079824 0.76 PTPN1 (0.50) SMN1; SMN2MAPTNTRK1POLB
SCHEMBL6080035 0.76 PTPN1 (0.59) SMN1; SMN2MAPTNTRK1POLB
SCHEMBL6079234 0.76 ABL1 (0.54) MEN1KMT2ARAB9AMAPTABL1
SCHEMBL6078593 0.76 GAA (0.43) MEN1KMT2ARAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2006-03-23 US disclosed
EP-1545523-A1 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS Astex Technology Limited (GB) 2005-06-29 EP disclosed
WO-2005002673-A1 RAF KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed
WO-2004004720-A1 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors MAPK1, MAPK3, MAPK10 CNR1 11/4885MEN1 4610/4885KMT2A 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.